Best of ASTRO 2018
Czech Republic
18. 3. 2019

Kongresové centrum Kunětická Hora Dříteč
09:15 - 09:30  Welcome  
Martin Dolezel

09:30 - 10:20  Track 1 – Gastrointestinal (Renata Soumarova)

Abstract 1: (LBA8) Preoperative Chemoradiotherapy Potentially Improves Outcome for (borderline) Resectable Pancreatic Cancer: Preliminary Results of the Dutch Randomized Phase III Preopanc Trial

Abstract 2: (55) Capecitabine Plus Oxaliplatin Versus Capecitabine Plus Oxaliplatin with Concurrent Radiation Therapy in the Treatment of Gastric Cancer after D2 Gastrectomy

Abstract 3: (56) A Prospective Study Assessing Early Cardiotoxicity after Trimodality Therapy for Esophageal Cancer

Abstract 4: (57) A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma

Abstract 5: (129) Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study

Abstract 6: (275) Predictors of Radiation-Induced Liver Disease in Patients with Hepatocellular Carcinoma Undergoing Proton Beam Therapy

Abstract 7: (276) Circulating Tumor DNA to Predict Surgical Outcome after Neoadjuvant Chemoradiation for Borderline Resectable/Locally Advanced Pancreatic Cancer

Abstract 8: (279) DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated with Veliparib, Gemcitabine and Radiation Therapy
Abstract 1: (166) Pre-Treatment [F-18]FDG-PET SUVmax as a Prognostic and Radiogenomic Marker in Cervical Cancer

Abstract 2: (167) Global Immune Profiling of Cervical Tumors Reveals a Protective T-Follicular Helper Cell Response Induced by Radiation Therapy

Abstract 3: (168) Molecular Targeting to Expand the Therapeutic Ratio in Women with Curable Cervical Cancer

Abstract 4: (171) Chemoradiation Therapy for Vulvar Squamous Cell Carcinoma: Does p16-Positivity Predict for Better Response Rates and Outcomes?

Abstract 5: (172) A Prospective Study of IMRT Versus 3D-CRT for Post-Operative Cervical Cancer Patients.

Abstract 6: (174) Small Cell Carcinoma of the Cervix: Definitive Chemoradiation for Locally Advanced Disease
11:15 - 12:05  Track 3 – Genitourinary (Karel Odrazka)

**Abstract 1: (LBA5)** Short Term Androgen Deprivation Therapy Without or with Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

**Abstract 2: (3)** Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

**Abstract 3: (4)** Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large-Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials

**Abstract 4: (60)** 10-Year Update of a Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer

**Abstract 5: (62)** Long-Term Update of NRG Oncology RTOG 94-08

**Abstract 6: (199)** International Multicenter Validation of an Intermediate-Risk Subclassification of Men Treated with Radical Treatment Without Hormone Therapy

**Abstract 7: (205)** Toxicity and Biochemical Outcomes after Dose Intensified Post-Operative Radiation Therapy for Prostate Cancer: A Randomized, Controlled, Phase 3 Trial

**Abstract 8: (217)** Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study

**Abstract 9: (297)** Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed Stereotactic Body Radiation Therapy

**Abstract 10: (299)** Local Failure and Gleason Score 9-10 Disease Independently Predict for Survival Outcomes: A Meta-Analysis of Six Randomized Trials
12:05 - 12:45  Track 4 – Lung (Jakub Cvek)

Abstract 1: (LBA3) Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial

Abstract 2: (LBA10) PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Abstract 3: (15) A Phase II Trial of Stereotactic Body Radiation Therapy for Operable T1N0M0 Non-Small Cell Lung Cancer. Japan Clinical Oncology Group (JCOG0403): Long Term Follow-up Results

Abstract 4: (20) An Externally Validated Nomogram for Predicting Distant Metastasis after Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer: Implications for Adjuvant Systemic Therapy

Abstract 5: (21) Local Control Analyses of Pulmonary Oligometastases Treated By Stereotactic Body Radiation Therapy (SBRT) from a Multi-institutional Survey in Japan

Abstract 6: (189) Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated with First-Line EGFR-TKIs
14:00 - 14:30  Track 5 – Best of the Rest (Martin Dolezel)

Abstract 1: An individual-patient pooled analysis from the international radiosurgery oncology consortium for kidney (IROCK)

Abstract 2: SABR-COMET: Stereotactic Radiation for the Comprehensive Treatment of Oligometastatic Cancers – Results of a Randomized Study

Abstract 3: ASTRO Guidelines Highlight Session

- Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
- Radiation Therapy for Pancreatic Cancer: An ASTRO Evidence-Based Guideline

Abstract 4: First-In-Human Clinical Experience With Real-Time Tumor Targeting Via MLC Tracking for Stereotactic Radiotherapy of Lung Cancer
Abstract 1: (LBA1) Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804

Abstract 2: (LBA2) FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015)

Abstract 3: (85) Reconstruction Failure Rates in Breast Cancer Patients with Two-Stage Expander/Implant Reconstruction Receiving Regional Nodal Irradiation with VMAT: Early Results of a Phase II Trial

Abstract 4: (89) Risk of Radiation Pneumonitis Following Individualized Modern Radiation Therapy with IMRT, a Breath-Holding Technique and Prone Positioning for Breast Cancer

Abstract 5: (90) Comparing 10 Year Outcomes in Radiated Patients with Breast Autologous Reconstruction (AR) or Tissue Expander/Implant Based Reconstruction (TE/I)

Abstract 6: (132) Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer

Abstract 7: (133) Gene Expression Changes Predict Acute and Late Toxicity to Combined PARP1 Inhibition and Radiation (RT) in High Risk Breast Cancer Patients- Results of the Biomarker Analysis of TBCRC 024

Abstract 8: (136) Phase I Trial of Stereotactic Body Radiation Therapy(SBRT) to Multiple Metastatic Sites: A NRG Oncology Study

Abstract 9: (162) Influence of Hypofractionated Radiation Therapy Following Mastectomy on Complication in Breast Cancer Patients Undergoing Two-Stage Prosthetic Breast Reconstruction
Abstract 1: (LBA4) NRG-RTOG 1016: Phase III Trial Comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the Oropharynx

Abstract 2: (LBA6) Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal Cancer

Abstract 3: (1) Eliminating Post-operative Radiation to the Pathologically Node Negative Neck: Long-Term Results of a Prospective Phase II Study

Abstract 4: (40) The Influence of Smoking and Age on Pathologic Features and Outcomes in Oral Cavity Squamous Cell Cancer: A Multi-institutional Collaborative Study


Abstract 6: (43) Margin Status, Lymphovascular Invasion, and Number of Neck Levels Involved Predict Distant Failure in p16+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Transoral Robotic Surgery (TORS)

Abstract 7: (223) A Randomized, Placebo (PBO) Controlled, Double-Blind P2b Trial of GC4419 (Avisopasem Manganese) to Reduce Severe Radiation-Related Oral Mucositis (SOM) in Patients with Locally Advanced Squamous Cell Cancer of the Oral Cavity (OC) or Oropharynx (OP)

Abstract 8: (228) Smoking Cessation Had Good Impact on Clinical Outcomes in Patients with Head and Neck Squamous Cell Carcinoma Receiving Curative Chemoradiotherapy

Abstract 9: (258) The Long-term Results of Adding Chemotherapy to Intensity-Modulated Radiation Therapy in the Treatment of Stage II Nasopharyngeal Carcinoma - A Multicenter Phase 2 Study
Abstract 1: (LBA9) Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001

Abstract 2: (92) Elevated MGMT Gene Expression Is Independently Associated with Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma

Abstract 3: (96) A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis

Abstract 4: (98) Risk Factors for Progression of Low Grade Glioma Following Gross Total Resection and Observation in the Molecular Era

Abstract 5: (290) Improved Survival Following Immunotherapy in Patients with Lung and Melanoma Primaries Metastatic to the Brain Treated with Upfront Stereotactic Radiosurgery

Abstract 6: (291) Preoperative Radiosurgery For Resected Brain Metastases: Updated Analysis of Efficacy and Toxicity Of A Novel Treatment Paradigm

Abstract 7: (293) A Phase II Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases

Abstract 8: (1024) Dosimetric Predictors of Cognitive Decline in Attention and Processing Speed after Fractionated Brain Radiation Therapy
Kontakt: dolezelm@email.cz
Doc. MUDr. Martin Doležel, Ph.D.
KOC Pardubického kraje, Kyjevská 44,
532 03 Pardubice
www.multiscan.cz

Kongresové centrum Kunětická Hora Dříteč
Dříteč 155, 533 05
GPS: 50°6'41.669"N, 15°49'9.128"E
http://grkh.cz/kongres/

Vzdělávací akce je pořádána dle Stavovského předpisu ČLK č. 16,
bude ohodnocena příslušným počtem kreditů.

Výše účastnického poplatku je 150 Kč (platba na místě).

Prosím o elektronické přihlášení na mail (dolezelm@email.cz),
nejpozději do 12. 3. 2019.